Navigation Links
ATS Medical Announces Third Quarter 2009 Results
Date:11/2/2009

apy, the ATS 3f® brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive, sutureless procedures. The ATS 3f® portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus® annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze® products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze® products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Cautionary Statements

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most rece
'/>"/>

SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Corporation (Nasdaq: DRRX ) announced today financial ... Total revenues were $4.3 million for the three months ... ended December 31, 2013.  Net loss was $5.9 million ... compared to a net loss of $5.1 million for ... and net loss was $22.1 million for the year ...
(Date:3/2/2015)... 2015 Click here for additional information on ... DPLO ), the nation,s largest independent specialty pharmacy, ... 31, 2014. All comparisons, unless otherwise noted, are to the ... Fourth Quarter 2014 Highlights include: , Revenue of ... dispensed of 208,000, an increase of 11% , Gross ...
(Date:3/2/2015)... N.J. , March 2, 2015 BD ... a leading global medical technology company, today announced the ... Diego -based medical technology company dedicated to improving ... acquisition furthers BD,s position in helping address preventable medication ... and CRISI entered into an exclusive partnership in June ...
Breaking Medicine Technology:DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 2Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 3Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 4Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 6Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 7Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 8Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 9Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 10Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 11Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 13Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 14Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 15Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 16Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 17Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 18Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 19Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 20Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 21BD Acquires CRISI Medical Systems 2BD Acquires CRISI Medical Systems 3
... Reportlinker.com announces that a new market research ... Chinese Pharmaceutical Regulatory Report 2011 ... This report includes a brief ... in China, as well as a discussion ...
... 25, 2011 Reportlinker.com announces that a ... its catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284719/Triple-Analysis-Lymphoma-Prostate-Cancer-and-Antibodies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology This ... strategies in both Lymphoma and Prostate Cancer ...
Cached Medicine Technology:Reportlinker Adds Chinese Pharmaceutical Regulatory Report 2011 2Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 2Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 3Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 4Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 5
(Date:3/2/2015)... 02, 2015 After a rigorous evaluation ... service, pricing and long-term strategy, Blood Centers of America ... choice for member centers’ testing needs. , BCA, which ... more than 30 percent of the U.S. blood supply, ... “BCA is committed to drive cost savings to members,” ...
(Date:3/2/2015)... 02, 2015 New York singer/songwriter ... be delivering a plenary address entitled Finding the ... Art of Healing and Recovery at this year’s ... Healthcare Executive Summit (BHES).     , With more than ... have been recorded by some of the biggest ...
(Date:3/2/2015)... 02, 2015 Over the last five ... leading vendors seeking to expand their geographic presence and ... expected to reach $6.2 billion by 2019 at CAGR ... including the U.S. and Canada and a major part ... developing regions such as Asia-Pacific including China and India, ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The ... grow at a CAGR of 6.1% to reach ... 2014. , Factors such as advantages of ... healthcare costs owing to minimally invasive surgeries and ... population are driving the global minimally invasive surgical ...
(Date:3/2/2015)... 2015 LegitScript, LLC, operator ... programs, including those for Internet pharmacy certification, ... and classification, has launched a certification program ... new program, called iCareRx , provides ... the identity of the owner/operator of Internet ...
Breaking Medicine News(10 mins):Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2
... Honey is sweeter, has lesser calories, healthful antioxidants and ... table sugar for people who want to lose// weight. ... San Diego State University studied buckwheat honey and clover ... honey from Florida, reported the online edition of the ...
... influences of paternity on the brain, delved into the ... resemblance with humans. Tiny monkeys called marmosets, whose brains ... into how fatherhood can actually instigate changes in ... were structural changes in the brain of the marmoset ...
... myotonic dystrophy in adults, which is the most common type ... // br>,Doctors at the University of Virginia Health System have ... poisonous RNA (ribonucleic acid) in muscle cells could result in ... 40,000 people in the United States have myotonic muscular dystrophy ...
... children who are highly sensitive to allergies in the first ... asthma. // ,Sabina Illi and colleagues at the University ... of exposure to allergens in early life and the effect ... function and asthma. They had reported their findings in the ...
... have succumbed to an outbreak of mosquito-borne encephalitis B in ... in addition to the 26 people already killed by the ... have been infected with the disease and 40 of them ... were detected in the first six months of 2006. But ...
... survey by Australian Bureau of Statistics (ABS) found that the number ... In the new figures released by// ABS, they have noted ... ,About two million Australians were found to be ... men were still more likely to be drinking more, the survey ...
Cached Medicine News:Health News:Toxic Strand Of RNA Causes Myotonic Muscular dystrophy 2Health News:Babies Prone To Allergies More likely To Be Asthmatic 2
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint, reaction is complete in five minutes at 37C. Wavelength: 540 nm. Linearity: 1000 mg/dL (11.3 mmol/...
For the quantitative determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
Medicine Products: